Chester County News and Community Website
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) announced that it has completed the rolling submission of its Biologics License Application (BLA) for INO-3107, a DNA-based immunotherapy candidate for adults with …
INOVIO Submits FDA Application for First DNA Therapy to Treat Rare HPV Disease Read More PLYMOUTH MEETING, PA — Biotechnology firm INOVIO (NASDAQ: INO) has granted a stock option award to a newly hired employee under its 2022 Inducement Plan, part of the company’s ongoing …
INOVIO Grants Equity Award to New Hire Under 2022 Inducement Plan Read More PLYMOUTH MEETING, PA — Biotechnology firm INOVIO (NASDAQ: INO) announced it will release its third-quarter 2025 financial results after the market closes on Monday, November 10, followed by a live …
INOVIO to Report Q3 Results and Business Update on November 10 Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) announced that it will participate in a virtual fireside chat at the upcoming Stephens Biotechnology Virtual Fireside Chat Conference on Tuesday, November 4, …
INOVIO to Present at Stephens Virtual Biotechnology Conference on November 4 Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) announced that results from its Phase 1 proof-of-concept trial evaluating DNA-encoded monoclonal antibodies (DMAbs) for COVID-19 have been published in Nature Medicine. The …
INOVIO’s DNA-Encoded Antibody Trial Shows Durable In Vivo Expression Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) announced that it has granted a stock option to a newly hired employee under the company’s 2022 Inducement Plan, as approved by the …
INOVIO Announces Equity Grant Under 2022 Inducement Plan Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) announced it will present new data on its lead product candidate INO-3107, a potential treatment for Recurrent Respiratory Papillomatosis (RRP), at several upcoming …
INOVIO to Present Key Data on DNA Medicines at Global Scientific Conferences Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) announced that the U.S. Food and Drug Administration has agreed to the company’s rolling submission timeline for its Biologics License Application (BLA) for …
INOVIO Advances FDA Submission for INO-3107 in Rare Disease Treatment Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) announced that a pre-recorded presentation will be available on demand as part of the H.C. Wainwright 27th Annual Global Investment Conference in New …
INOVIO to Present at H.C. Wainwright Global Investment Conference Read More PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) reported second quarter 2025 financial results and outlined key milestones in its effort to bring INO-3107, a DNA medicine candidate for recurrent respiratory …
INOVIO Advances Toward FDA Filing for INO-3107 as Quarterly Losses Narrow Read More